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Summary
Cellular levels of key regulatory proteins are controlled via ubiquitination and subsequent degradation. Deubiquitinating
enzymes or isopeptidases can potentially prevent targeted destruction of protein substrates through deubiquitination prior
to proteasomal degradation. However, only one deubiquitinating enzyme to date has been matched to a specific substrate
in mammalian cells and shown to functionally modify it. Here we show that the isopeptidase USP2a (ubiquitin-specific
protease-2a) interacts with and stabilizes fatty acid synthase (FAS), which is often overexpressed in biologically aggressive
human tumors. Further, USP2a is androgen-regulated and overexpressed in prostate cancer, and its functional inactivation
results in decreased FAS protein and enhanced apoptosis. Thus, the isopeptidase USP2a plays a critical role in prostate
cancer cell survival through FAS stabilization and represents a therapeutic target in prostate cancer.
Introduction proteasomal level. In addition, we sought to determine their
potential substrates. Using degenerate primers complementary
Ubiquitination of targeted substrates is a reversible process. to the conserved isopeptidase catalytic motifs, the CYS and
Ubiquitin processing proteases (Ubps) are cysteine proteases HIS boxes, and RACE-PCR, several full-length cDNAs encoding
also known as deubiquitinating enzymes or isopeptidases (Wil- isopeptidases were obtained from RNA preparations of both
kinson, 2000). Despite the large number of Ubps identified, little intact and androgen-deprived (castrated) rat prostate. The most
is known about their physiological roles or their substrates. Ubps abundantly expressed cDNA in the preparation from the pros-
may “edit” the number of ubiquitin moieties in the polyubiquitin tate with an intact androgen environment was Ubp69. Ubp69
chain of poorly or erroneously ubiquitinated proteins or generate is a product of a gene which also gives rise to an alternatively
free ubiquitin from polyubiquitin chains released after proteaso- spliced form, called Ubp45 (Park et al., 2002). These isopepti-
mal activity. More importantly, a preproteasomal action for iso- dases are also known as Ubp-t2 and Ubp-t1, respectively (Lin
peptidases has been hypothesized, resulting in the cleavage of et al., 2000, 2001). We then utilized the LNCaP prostate cancer
the polyubiquitin tag from specific substrates, preventing and cell line to obtain its human homolog, USP2, and characterized
modulating their degradation. In fact, the deubiquitinating en- the gene structure on chromosome 11q23.3 (Figure 1A). Since
zyme HAUSP (USP7) has been shown to stabilize p53 through the official human nomenclature for the gene known to be coded
deubiquitination even when the ubiquitin ligase mdm2 is in ex-
by this locus is USP2 (GenBank # NM_004205), we renamedcess (Li et al., 2002). These findings confirm the existence and
the human splice variants USP2a (GenBank # NP_004196) andthe importance of preproteasomal isopeptidases. In this report,
USP2b (GenBank # NP_741994). We also identified putativewe show that the isopeptidase USP2a is a preproteasomal,
androgen-regulatory elements in the immediate 5 upstreamandrogen-regulated isopeptidase and is a key regulator of pros-
region. The C terminus, shared by both USP2a and USP2b,tate cancer cell survival through the stabilization of FAS.
contains the canonical isopeptidase CYS and HIS boxes (Figure
1A). An antibody generated against the C terminus recognizesResults and discussion
both splice variants (Figure 1A, lane 1), while the USP2a-specific
one recognizes only the 69 Kd band (Figure 1A, lane 2).We intended to identify androgen-regulated deubiquitinating
enzymes expressed in the prostate and functioning at the pre- We next searched for proteins that interacted with USP2a.
S I G N I F I C A N C E
We report that the deubiquitinating enzyme USP2a functions at the preproteasomal level by preventing the degradation of fatty acid
synthase (FAS). FAS overexpression occurs in the majority of epithelial tumors, including prostate cancer, and protects cancer cells
from apoptosis. Because USP2a is overexpressed in prostate cancer and its inhibition results in apoptosis of transformed prostatic
cells, this isopeptidase may be targeted to induce apoptosis in prostate cancer cells.
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Figure 1. Chromosomal arrangement of the
USP2 gene and its two splice variants
USP2a and b on chromosome 11q23.3. The ho-
mology between rat Ubp69 and human USP2a
is 88% and between Ubp45 and USP2b is 90%.
The numbers above and below the scheme rep-
resent the size in base pair of the introns and
exons, respectively. An antibody raised against
the USP2 region common to both splice variants
(black boxes) recognizes both USP2a and b in
an immunoblot analysis of LNCaP cell protein
lysate. The anti-USP2a-specific antibody raised
against the N terminus of USP2a (hatched boxes)
recognizes only the 69 Kd form.
The androgen-dependent LNCaP cells were grown in the pres- band was analyzed by mass spectrometry and identified as
being fatty acid synthase (FAS) (Figure 2B). The interaction be-ence of 10% fetal bovine serum (FBS) or in androgen-deprived
(charcoal stripped—cd) FBS for 48 hr. These two cell culture tween USP2a and FAS was then confirmed by coimmunopreci-
pitation performed in vitro (Figure 2C, lane 3) and reciprocalconditions were utilized because they reflected the intact and
castrate rat prostate environments in vivo, respectively. LNCaP coimmunoprecipitation in vivo (Figure 2C, lanes 6 and 9). Finally,
USP2a and FAS proteins colocalized in the cytoplasm of LNCaPcells were metabolically labeled with 35S-methionine. The protein
lysates were then incubated with Ni-NTA resin coupled with the cells (Figure 2D).
Next, we sought to determine whether USP2a is an andro-recombinant his-tagged USP2a, and one prominent band of
approximately 250 kDa was detected (Figure 2A). This band was gen-regulated gene. LNCaP cells were grown in charcoal-
stripped serum. Addition of dihydrotestosterone (DHT) to thestronger in lysates prepared with cells grown in the presence of
FBS than in charcoal-stripped, androgen-depleted conditions medium induced, while the anti-androgen bicalutamide (Caso-
dex) blocked, the expression of endogenous USP2a (Figure 3A,(cd-FBS), and absent in the uncoupled Ni-NTA. The 250 kDa
Figure 2. USP2a interacts with fatty acid synthase
(FAS)
A: Gradient SDS-polyacrylamide gel of eluted
proteins from the affinity chromatography: the
arrows indicate the FAS band, which was
stronger in LNCaP cells grown in the presence of
FBS than with charcoal-stripped serum.
B: Mass spectrometry analysis of the band.
C: FAS is coimmunoprecipitated in vitro with the
recombinant 6his-USP2a (left panel, lane 3), and
in vivo after transient transfection and overex-
pression of USP2a (middle panel, lane 6). USP2a
is identified by immunoblotting after immuno-
precipitation of endogenous FAS (right panel,
lane 9).
D: Immunofluorescence of USP2a (FITC—green)
and FAS (rhodamine—red) demonstrating their
colocalization in prostate cancer cells (right
panel—nuclei counterstained with DAPI).
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when compared to control cells (Figure 4A, lanes 3 and 4).
Immunofluorescence with anti-FAS antibodies confirmed the
accumulation of cytoplasmic FAS in LNCaP cells treated with
proteasome inhibitors (Figure 4A). Importantly, ubiquitinated
isoforms of FAS were identified by FAS immunoprecipitation
followed by anti-ubiquitin immunoblot (Figure 4B). Finally, using
pulse-chase experiments, proteasomal inhibition was able to
significantly extend FAS protein half-life from 12.2 to 40.9 hr
(Figure 4C). These results indicate that FAS is regulated by the
ubiquitin-proteasome system in human cells.
Next, we confirmed that the catalytic core of USP2 (lacking
the N terminus) has in vitro deubiquitinating activity as previously
described (Lin et al., 2000, 2001) (Figure 5A, lane 4). In order
to show that the ubiquitination state of FAS in vivo depends on
USP2a, siRNAs designed to bind to the 5 region specific to
the USP2a isoform were utilized in the presence of proteasome
inhibitors and FAS ubiquitination was determined. Indeed, FAS
ubiquitination was highest in LNCaP cells treated with both anti-
USP2a siRNA and MG-132 (Figure 5B, lane 3).
In order to assess the role of USP2a in vivo, we transiently
transfected LNCaP cells with both wild-type and mutant USP2a
(276 Cys to Ala). Mutations in the cysteine box have tradition-
ally been utilized to obtain catalytically inactive isopeptidase
mutants which have been shown to often act as dominant nega-
tives (DeSalle and Pagano, 2001; Li et al., 2002; Naviglio et al.,
1998). Four hours after cycloheximide treatment, FAS protein
levels decreased in LNCaP cells transfected with vector (Figure
5C, lane 3, upper panel) or, even more significantly, with mutant
USP2a (Figure 5C, lane 9, upper panel), while wild-type USP2aFigure 3. USP2a is regulated by androgens
protected FAS from degradation (Figure 5C, lane 6 comparedA: Dihydrotestosterone (DHT) induces USP2a as well as FAS and AR protein
to lanes 3 and 9, upper panel). Neither the wild-type nor theexpression in LNCaP cells grown in charcoal-stripped serum. Induction of
all three proteins is blocked by the anti-androgen bicalutamide (Casodex) catalytic inactive mutant of the unrelated isopeptidase UNP
(right panel). (DeSalle et al., 2001) had an effect on FAS stability (data not
B: mRNA levels of rat Ubp69 (homolog of the human USP2a) and of FAS shown). Thus, USP2a protects FAS from degradation in vivo.
assessed by quantitative PCR in the rat prostate at castration (time 0) and
To further understand the role USP2a plays in the regulationduring regeneration (at the times shown) after testosterone replenishment
of FAS metabolism, we blocked USP2a expression in LNCaP(bar graph). Western blots of USP2a, FAS, AR, and  actin are shown below.
mRNA levels of Ubp69 progressively increase after testosterone proprionate cells with antisense oligonucleotides. Transfected cells were
(TP) stimulation, while protein levels increase at 48 hr and then stabilize. FACS-selected on the basis of cotransfection of CD19 in a 3:1
ratio. USP2a mRNA levels were reduced by approximately 90%
in cells transfected with anti-USP2a oligonucleotides. As ex-
pected, protein levels were comparably suppressed (Figure 6A).
top panel). FAS mRNA is known to be induced by androgens Importantly, FAS protein levels were significantly reduced, de-
in prostate cancer cells (Kuhajda, 2000; Swinnen et al., 2000). spite unaltered FAS mRNA levels (Figure 6A). To investigate
As expected, both FAS and the androgen receptor (AR) were the biological consequences of FAS protein downregulation via
USP2a inhibition, we assessed changes in cell cycle kineticsinduced by DHT and blocked by Casodex (Figure 3A, middle
or induction of programmed cell death, since both had beenpanels). In addition, rat Ubp69 mRNA expression was progres-
reported as a result of direct inhibition of FAS. Apoptosis wassively induced by testosterone proprionate replenishment after
obtained by treating prostate cancer cells with USP2a antisensecastration in the regenerating prostate rat model (Waltregny et
oligonucleotides. As expected, a similar effect on apoptosis wasal., 2001) (Figure 3B). As expected, FAS mRNA and protein as
observed after treatment of LNCaP cells with cerulenin, a well-well as AR protein were upregulated by testosterone in the same
known inhibitor of FAS (Figure 6A). In fact, RNA interference ofmodel (Figure 3B). Taken together, these results demonstrate
FAS also results in apoptosis of LNCaP cells (Swinnen et al.,
that Ubp69/USP2a (hereon in referred to as USP2a) is regulated
2003). A slightly higher apoptotic rate was obtained when non-
by androgens. sorted LNCaP cells were treated with siRNA specific for USP2a
The association between USP2a and FAS prompted us to (Figure 6B) compared to antisense oligonucleotide treated cells.
investigate posttranscriptional FAS regulation. It had been pre- The mismatched control had no effect. The effect was also more
viously reported that the yeast homolog of FAS is regulated by protracted when compared to antisense oligonucleotides, since
ubiquitin-mediated degradation (Egner et al., 1993). Therefore, most cells treated with anti-USP2a siRNA (but not the scrambled
we next investigated whether the inhibition of the proteasome control) were apoptotic at 120 hr following transfection (data
activity affects FAS turnover in LNCaP cells. Five hours following not shown). No effect on the S phase fraction was observed
with either gene silencing or cerulenin (not shown). These resultslactacystin or MG-132 treatment, the FAS protein accumulates
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Figure 4. FAS is regulated by the ubiquitin-proteasome pathway
A: FAS protein levels increase in Lactacystin (Lac) or MG132 (MG) treated (5 hr) LNCaP cells (lanes 3 and 4) compared to control (lane 2). Lane 1 shows
endogenous levels of FAS. Cytoplasmic accumulation of FAS occurs in LNCaP cells after proteasome inhibition (MG, middle panel).
B: Immunoprecipitation with anti-FAS antibodies followed by Western blot with anti-Ub polyclonal antibodies show the smear-like positivity of the ubiquitinated
isoforms of FAS in LNCaP cells. The reaction is strongest in protein extracts obtained from cells grown in charcoal-stripped serum (cd-FBS) (lane 3). The
membrane was stripped and reblotted with anti-FAS antibodies (bottom panel).
C: LNCaP cells were pulse-labeled with 35S-methionine, treated with 5 M of the proteasome inhibitor MG-132 or DMSO, the protein extracts immunoprecipi-
tated with antibodies against FAS, and autoradiography performed (left panel). The half-life of FAS shown in the semi-log plot (right panel) was extended
from 12.2 hr to 40.9 hr in the cells treated with MG-132.
suggest that the USP2a enzyme acts by inhibiting FAS protein against the N terminus of USP2a, we found overexpression of
USP2a protein in 51% of prostate tumors (Figure 7C). Thus,degradation by the proteasome, resulting in the protection of
prostate cancer cells from apoptosis. USP2a is overexpressed in a subset of prostate cancers both
at the mRNA and protein level.In order to prove this assumption, we generated LNCaP
cells stably transfected with FAS, which we called FASCaP. Despite the growing number of Ubp family members, their
physiological functions remain mostly unknown. The high num-This line expresses 2.3-fold levels of FAS protein and 8.7-fold
levels of FAS mRNA (Figure 6C, lane 2) compared to the parent ber and structural diversity of Ubps suggests that some of these
enzymes have specific targets. The protein levels of specificLNCaP cell line. When FASCaP cells were treated with siRNA
against USP2a, FAS protein levels remained persistently higher substrates may be controlled by the removal of polyubiquitin
chains, preventing and regulating their degradation. Here, wethan those in parent LNCaP cells, and no apoptosis was seen
(Figure 6D). Finally, Figure 6E demonstrates a knockdown of demonstrate that USP2a is an androgen-regulated isopeptidase
and that downregulating USP2a in prostate cancer destabilizesUSP2a protein (lanes 2 and 4) and mRNA (bar graphs) by the
specific siRNA in both LNCaP and FASCaP lines. In contrast, FAS leading to programmed cell death, thus establishing a link
between substrate regulation by a “preproteasomal” Ubp, aFAS protein levels diminish only in LNCaP untransfected cells.
These results strongly suggest that apoptosis resulting from metabolic enzyme, and prostate cancer. USP2a thus appears to
behave as an oncogene by stabilizing the antiapoptotic enzymeUSP2a inactivation is mediated by FAS.
To assess the relevance of the USP2a/FAS interaction in FAS.
FAS plays a central role in de novo lipogenesis. In addition,human prostate cancer, USP2a expression levels were first ana-
lyzed in human prostate cell lines. USP2a is expressed in the tumor cells synthesize 95% of fatty acids de novo, despite
adequate nutritional supply (Ookhtens et al., 1984; Sabine etprostate cancer cell lines LNCaP, DU145, and PC3, but not in
normal primary prostate epithelial (PrEC) cells (Figure 7A). We al., 1967; Weiss et al., 1986). FAS is overexpressed in prostate
cancer, while overexpression has been associated with aggres-then assessed USP2a expression in human normal and tumor
tissues by semiquantitative RT-PCR followed by densitometry sive biologic behavior, suggesting a functional role for fatty acid
synthesis in the growth or survival of cancer cells (Dhanasekaran(Figure 7B). Indeed, 46% of tumor samples showed increased
expression of USP2a mRNA compared to the corresponding et al., 2001; Kuhajda, 2000; Rossi et al., 2003; Singh et al.,
2002a). Importantly, FAS is overexpressed in metastases arisingnormal. Finally, utilizing the polyclonal antibody we generated
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Figure 5. USP2a deubiquitinates FAS and protects it from proteasome-mediated degradation
A: Recombinant GST-Polyubiquitin was incubated in presence or absence of Ubiquitin-aldehyde with recombinant core USP2 (lacking the N terminus) for
30 min at 37C. The FK2 antibody (Affiniti Research Products, Exeter, UK) was used to detect polyubiquitin in the Western blot. The catalytic core of USP2
degraded polyubiquitin chains (lane 3), while ubiquitin aldehyde almost completely inhibited core-USP2-mediated polyubiquitin degradation activity
(lane 4).
B: Incremental ubiquitination of FAS is seen starting with untreated LNCaP cells (lane 1), in LNCaP cells treated with MG-132 (lane 2), and in LNCaP cells
treated with anti-USP2a siRNA as well as proteasome inhibitor (lane 3).
C: FAS protein levels in LNCaP cells treated with cyclohexamide and transfected with empty vector (lanes 1–3), wild-type USP2a (lanes 4–6), and catalytic
inactive mutant (276 Cys to Ala) USP2a (lanes 7–9). Membranes were stripped and reblotted with anti-USP2a antibodies (lower panel). Quantitation of
the 4 hr time points normalized to the 0 hr control show that wild-type, but not mutant USP2a, prevents degradation of FAS.
in the TRAMP mouse model of prostate cancer (Pflug et al., spite hypoxic conditions, possibly preventing mitochondrial ini-
tiation of the apoptotic cascade.2003) and, together with its transcriptional regulator steroid reg-
ulatory element binding protein-1 (SREBP1), in human prostate Not only do FAS inhibitors, such as C75, the mycotoxin
cerulenin, and interference of FAS message result in apoptosiscancer metastatic to bone (Rossi et al., 2003).
Taken together, direct inactivation of FAS (Swinnen et al., of prostate cancer cells in culture (Kuhajda et al., 2000; Swinnen
et al., 2003), but they also result in decrease tumor size in animal2003) and the results we obtained suggest that FAS overexpres-
sion confers selective advantage to prostate cancer cells by models of prostate cancer that overexpress the enzyme (Pflug
et al., 2003; Pizer et al., 2001), underscoring the relevance ofinhibiting apoptosis. While the mechanism by which FAS over-
expression protects cancer cells from apoptosis is still not FAS inhibition in vivo. Targeting FAS directly in cancer, however,
may result in undesirable side effects such as anorexia andknown, several hypotheses have been put forth. First, it has
recently been shown that FAS plays a major role in the synthesis significant weight loss (Clegg et al., 2002), and may even have
teratogenic consequences (Chirala et al., 2003). Since we showof cellular membrane phospholipids (Swinnen et al., 2003). Alter-
ations in membrane lipid composition may, in turn, have pro- here that FAS protein levels are modulated via deubiquitination
found effects on relevant signal transduction pathways, such by USP2a (Figure 8), our data suggest that FAS downregulation
as the phosphatidylinositol 3-kinase pathway (Van de Sande with the resultant induction of programmed cell death could be
et al., 2002). Alternatively, the cytotoxicity which occurs as a achieved by targeting USP2a in prostate cancer.
result of FAS downregulation may be attributed to direct activa- In conclusion, the results of the present study indicate that
tion of apoptotic pathways. In fact, FAS inhibition results in the USP2a is a preproteasomal, androgen-regulated isopeptidase
release of cytochrome c and caspase activation (Heiligtag et al., and is a key regulator of prostate cancer cell survival via the
2002). Finally, FAS overexpression may restore redox balance in stabilization of FAS protein. USP2a may represent a potential
limiting oxygen conditions. Specifically, excessive lactate pro- therapeutic target in prostate cancer.
duced by anaerobic glycolysis limits the respiratory chain and
Experimental proceduresresults in decreased oxidizing power. Interestingly, both lower
organisms tolerant to hypoxia and prostate cancer cells favor
Degenerate PCR and RACE RT-PCRsynthesis and chain elongation of fatty acids because they sup-
One microgram of total RNA from the rat prostate was reverse-transcribed
ply oxidizing power for key oxidative steps (Hochachka et al., and used to PCR-amplify the CYS and HIS boxes with the following primer
2002). Thus, overexpression and enhanced activity of FAS set: Cys-box primer: 5 AAC CTG GG(C,G) AAC AC(C,T) TGC T(G,T)C ATG
AAC 3; His-box primer: 5 GTT CTT C(C,T,A)C (A,G)TA (G,T)G(T,C) (A,G)GTwould result in a significant improvement in redox balance de-
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Figure 6. Antisense oligonucleotides and siRNA
against USP2a induce apoptosis in prostate can-
cer cells
Apoptosis is rescued by FAS overexpression.
A: Antisense experiment in LNCaP cells. mRNA
(RT-PCR) and protein (WB) levels of USP2a and
FAS from CD19-sorted LNCaP cells transfected
with antisense (AS) or sense (S) oligonucleotides.
USP2a mRNA levels were reduced by approxi-
mately 90%, and FAS mRNA levels were not af-
fected. Western blot reactions show a 33% de-
crease in USP2a and a 50% decrease in FAS levels
(average of three experiments shown in histo-
gram) in the cells transfected with AS oligonucle-
otides for USP2a. AS oligonucleotides to USP2a,
as well as the FAS inhibitor cerulenin, induce apo-
ptosis.
B: siRNA experiment in LNCaP cells. siRNA against
USP2a, but not the mismatched siRNA, induces
apoptosis in LNCaP cells. Quantitation of apo-
ptosis in unselected LNCaP cells was measured
by CaspACE/FACS analysis following anti USP2a
siRNA or nonsilencing siRNA in four independent
experiments. SSC (x axis) refers to cell granularity
and FL (y axis) represents fluorescence of cells.
C: Quantitation of FAS protein (2.3) and mRNA
(8.7) by qPCR in LNCaP cells stably transfected
with FAS (FASCaP cells).
D: siRNA experiment in FASCaP cells. FAS overex-
pression rescues apoptosis in LNCaP cells: apo-
ptosis is not induced by siRNA against USP2a in
FASCaP cells.
E: Levels of USP2a mRNA and protein decrease
in both lines (lanes 2 and 4), while FAS protein
levels diminish only in LNCaP untransfected cells
(lane 2, upper blot), but not in FASCaP cells (lane
4, upper blot).
GTA GTG GCC 3. The SMART RACE cDNA Amplification Kit (Clontech, was normalized by GAPDH. Real-time RT-PCR on the rat prostates and
LNCaP cells was performed using an ABI-PRISM 7700 Sequence DetectorPalo Alto, CA) was utilized to obtain the full-length cDNAs.
and the SYBR Green PCR Core Reagent kit (PE Applied Biosystems, Foster
City, CA), as previously described (Waltregny et al., 2001). All samples wereSemiquantitative and real-time RT-PCR
One microgram of RNA from castrate or testosterone-replenished rat pros- run in triplicate, and the relative amounts of Ubp69, USP2a, FAS, rat, and
human GAPDH mRNAs calculated by comparison with standard curves.tates, as well as normal and neoplastic human prostate and LNCaP cell
lines, were reverse-transcribed with random primers and amplified with FAS,
Ubp69, and USP2a-specific primers. The sequences for rat Ubp69 and FAS Affinity chromatography and mass spectrometry
His-tagged USP2a coupled to Ni-NTA beads (Qiagen, Valencia, CA) wasprimers are 5 CAG ACC CGT GGC AAT GAA A 3 (Ubp69 forward), 5 GCT
GTT CGA TTT CTT CTG GC 3 (Ubp69 reverse), 5 CCT CAG TCC TGT TAT incubated for 1 hr at 4C with 300 g of a 35S-labeled LNCaP cell lysate in
a buffer containing 50 mM NaH2PO4 (pH 8.0), 150 mM NaCl, 1 mM PMSF,CAC CCG A 3 (FAS forward), and 5 GCT GAA TAC GAC CAC GCA CTA
3 (FAS reverse). The sequences for the human USP2a and FAS primers are 10 g/ml soybean trypsin inhibitor, 1 g/ml aprotinin (Roche Molecular
Diagnostics, Indianapolis, IN), 2 mM NEM (Sigma, St. Louis, MO), and 1005 ATG CTT GTG CCC GGT TCG AC 3 (USP2a forward), 5 CTA CAT TCG
GGA GGG CGG GCT 3 (USP2a reverse), 5 CAGCCATGGAGGAGGTGGT M MG-132 (Oncogene Research Product, La Jolla, CA). Following extensive
washing with the same buffer, the Ni-NTA pellets were resuspended andGATT 3 (FAS forward), 5 GGGACATGCCTAACACCTACGTCTA 3 (FAS
reverse). For semiquantitation on the human samples, the PCR products boiled for 5 min in Laemmli buffer, and the eluted proteins resolved in
4%–20% gradient SDS-polyacrylamide gels and exposed to X-Omat ARwere visualized on 1.3% agarose gels stained with ethidium bromide and
analyzed using the Kodak 440CF imager. The expression of USP2a cDNAs films (Eastman Kodak Co., Rochester, NY). To identify the USP2a interactors,
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(Figure 2C, lane 3). For endogenous in vivo coimmunoprecipitation experi-
ments, USP2a was overexpressed in LNCaP cells, and FAS immunoblotting
was performed on anti-USP2a immunoprecipitate (Figure 2C, lane 6). Anti-
USP2a immunoblot was performed on anti-FAS immunoprecipitate in un-
transfected cells (Figure 2C, lane 9).
Proteasome inhibitor treatment
LNCaP cells were incubated in RPMI 1640 medium containing the protea-
some inhibitors Lactacystin (final concentration of 20 M) (Oncogene Re-
search Product, La Jolla, CA) or MG132 (50 M) (Oncogene Research Prod-
uct, La Jolla, CA) for 5 hr before being harvested for protein extraction (with or
without prior FAS immunoprecipitation) or fixation for immunofluorescence.
Pulse chase
LNCaP cells were washed with methionine- and cysteine-free RPMI (In-
vitrogen, Carlsbad, CA) and pulse-labeled with 25 Ci/ml of 35S-methionine
(Perkin Elmer Life Sciences, Boston, MA) for one hour. Cells were then
incubated for 5, 15, and 25 hr in RPMI with 10 M of MG-132 or the
equivalent amount of DMSO, harvested with cold PBS, and used to prepare
protein lysates. Fifty micrograms of each lysate were immunoprecipitated
for 12 hr at 4C with 8 g of anti-FAS antibodies (Transduction Laboratories,Figure 7. USP2a is overexpressed in prostate carcinoma
Lexington, KY) and incubated with protein G-Sepharose for 1 hr at 4C.
A: Western blot analysis using the USP2a-specific antibody shows that USP2a Eluted proteins were resolved in 6% SDS-polyacrylamide gels and exposed
is expressed in prostate cancer cell lines LNCaP, DU145, and PC-3, but not
to X-ray films for 6–12 days at 80C.
in primary prostate (PrEC) cells.
B: RT-PCR for USP2a demonstrating tumor overexpression of the isopepti-
Generation of the stable FASCaP linedase. Densitometry shows increased expression of USP2a in tumor samples
To generate FASCaP, the LNCaP cell line stably expressing FAS, the 7536compared to adjacent normal tissue.
base pair human fatty acid synthase (FAS) cDNA was cloned into the pWZL-C: Immunohistochemistry using the USP2a-specific antibody shows abun-
blasticidin-resistant retrovirus vector. 293T packaging cells were cotrans-dant expression of USP2a in tumor tissue and no expression in the corre-
fected with retroviral vector pWZL-FAS and packaging plasmid pCL. Tissuesponding normal tissue. Mean values of USP2a gene expression in normal
culture supernatants containing retrovirus derived from transfected 293Tand tumor samples is shown on the right.
cells were used to infect LNCaP cells in the presence of 5 g/ml polybrene
(Sigma, St. Louis, MO). Successfully infected LNCaP cells were selected in
the presence of 1.5 g/ml blasticidin. Expression of transfected sequences
was confirmed by Western blotting and qRT-PCR.this experiment was scaled up, and the stained bands cut out from the gel
and analyzed by mass spectrometry (Maldi-TOF/Voyager DE/STR – Molecu-
In vivo androgen responsivenesslar Biology Core Facility, Dana-Farber Cancer Institute, Boston, MA). Among
LNCaP cells were grown in phenol red-free RPMI medium 1640 supple-the bands that exhibited good signals and significant matches using the
mented with 10% charcoal-dextran-stripped fetal bovine serum (cd-FBS)Protein Prospector Database (USCF), two were identified as being FAS (66%
for 48 hr and treated with 10 nM DHT in the presence or absence of 10 Mand 57% peptide match).
of bicalutamide (Casodex). The cells were washed, harvested at 0, 7, 24,
and 48 hr into 2 ml ice-cold phosphate-buffered saline, pelleted by centrifu-Coimmunoprecipitation
gation, and protein extracts immunoblotted with antibodies against USP2a,For in vitro coimmunoprecipitation, His-tagged USP2a protein was added
FAS, AR, and  actin.to LNCaP protein lysates and FAS was detected in the His immunoprecipitate
Rat prostate castration-regeneration model
Twelve-week-old male Noble rats were purchased from Charles River Labo-
ratories (Boston, MA). Fourteen days after surgical castration, rats were
injected with 6.6 mg/kg Testosterone Propionate (TP) (Sigma Chemical Co.,
St. Louis, MO) in tocopherol-stripped corn oil (ICN Biomedicals, Inc., Aurora,
OH) i.m., once a day, for 4 days. At 24, 48, 72, and 96 hr after the beginning
of TP injections, animals (seven rats per time point) were sacrificed by CO2
asphyxiation. The ventral prostate was then harvested, and immediately
flash frozen in liquid nitrogen for subsequent RNA and protein isolation.
Deubiquitination assay
The cDNA encoding the recombinant GST-Polyubiquitin (accession number
AB003730, GI:2627128 [Nenoi et al., 1998]; Invitrogen, Basel, Switzerland)
was subcloned into pGEX4T1 (Amersham Biosciences, Otelfingen, Switzer-
land), expressed in the E. coli strain BL21(DE3) (Invitrogen) and purified by
affinity chromatography on a GSTrap FF column according to the manufac-
turer’s recommendations (Amersham). 3.75g of recombinant GST-Polyubi-
quitin was incubated in presence or absence of 150 ng Ubiquitin-aldehyde
(Boston Biochem Inc., Cambridge, MA) with 150 ng of recombinant core
USP2 (lacking the N terminus) for 30 min at 37C.
Figure 8. Hypothetical model of FAS regulation by USP2a
Transfection with anti-sense oligonucleotides and siRNAFAS is transcriptionally regulated via steroid regulatory element binding pro-
Anti-sense (AS) oligonucleotides (Oligos Etc., Wilsonville, OR) were designedteins (SREBPs), which, in turn, are regulated by the ligand-activated andro-
to complement the 5 end of the USP2a coding region (GAG AGC TGG GACgen receptor (AR). USP2a, also androgen-regulated, stabilizes FAS and con-
tributes to tumor cell survival. ATC CTT CA). A scrambled (S) oligonucleotide (AAG ATC AGA GAC CTC
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ReferencesCGT CT) was used as control. The CD19 plasmid was cotransfected with
the antisense or sense oligonucleotides (3:1, w/w) in order to select by FACS
only the transfected cells. LNCaP cells were transfected for 36–46 hr with Chirala, S.S., Chang, H., Matzuk, M., Abu-Elheiga, L., Mao, J., Mahon, K.,
2 mg/ml of Lipofectin reagent (Invitrogen, Carlsbad, CA), 300 nM of AS or Finegold, M., and Wakil, S.J. (2003). Fatty acid synthesis is essential in
S oligonucleotides, and 0.19 nM of CD19 plasmid in OPTIMEM (Invitrogen, embryonic development: Fatty acid synthase null mutants and most of the
Carlsbad, CA). For protein and cell cycle analysis, cells were harvested after heterozygotes die in utero. Proc. Natl. Acad. Sci. USA 100, 6358–6363.
an additional 40 hr. The pellets were incubated with 1.5 l anti-CD19 FITC
Clegg, D.J., Wortman, M.D., Benoit, S.C., McOsker, C.C., and Seeley, R.J.conjugated (Caltag Laboratories, Burlingame, CA) at 4C for 2 hr, washed
(2002). Comparison of central and peripheral administration of C75 on foodtwice with cold PBS, stained with propidium iodide, and analyzed by flow
intake, body weight, and conditioned taste aversion. Diabetes 51, 3196–cytometry.
3201.For the siRNA (Qiagen-Xeragon, Germantown, MD) experiment, 2.5 
10e5 cells per 6 cm dish were seeded in RPMI 1640 medium containing DeSalle, L.M., and Pagano, M. (2001). Regulation of the G1 to S transition
10% FBS. 24 hr later, cells were transfected either with 80 nM anti-USP2 by the ubiquitin pathway. FEBS Lett. 490, 179–189.
siRNA, r(UGCUUGUGCCCGGUUCGAC)d(TT), or 80 nM nonsilencing control
DeSalle, L.M., Latres, E., Lin, D., Graner, E., Montagnoli, A., Baker, R.T.,siRNA, r(UUCUUCGAACGUGUCACGU)d(TT), using Oligofectamin (In-
Pagano, M., and Loda, M. (2001). The de-ubiquitinating enzyme Unp inter-vitrogen, Carlsbad, CA).
acts with the retinoblastoma protein. Oncogene 20, 5538–5542.
Apoptosis measurement
Dhanasekaran, S.M., Barrette, T.R., Ghosh, D., Shah, R., Varambally, S.,Forty-eight hours post siRNA transfection, cells were labeled by adding 10
Kurachi, K., Pienta, K.J., Rubin, M.A., and Chinnaiyan, A.M. (2001). Delinea-M of the CaspACE FITC-VAD-FMK apoptosis in situ marker (Promega,
tion of prognostic biomarkers in prostate cancer. Nature 412, 822–826.Madison, WI), a cell-permeable derivative of the pan-caspase inhibitor
Z-VAD-FMK binding to activated Caspase. After 20 min incubation in the Egner, R., Thumm, M., Straub, M., Simeon, A., Schuller, H.J., and Wolf, D.H.
dark, cells were trypsinized, washed with medium and PBS, and fluorescence (1993). Tracing intracellular proteolytic pathways. Proteolysis of fatty acid
was analyzed on a PARTEC PAS flow cytometer at 530 nm (excitation of synthase and other cytoplasmic proteins in the yeast Saccharomyces cere-
488 nm). Percentage of apoptotic cells was calculated by the FlowMax visiae. J. Biol. Chem. 268, 27269–27276.
software.
Heiligtag, S.J., Bredehorst, R., and David, K.A. (2002). Key role of mitochon-
dria in cerulenin-mediated apoptosis. Cell Death Differ. 9, 1017–1025.Transient transfection and cycloheximide chase experiments
QuikChange site-directed mutagenesis kit (Stratagene, Cedar Creek, TX) Hochachka, P.W., Rupert, J.L., Goldenberg, L., Gleave, M., and Kozlowski,
was used to construct the catalytic site inactive mutant USP2a (Cys276Ala). P. (2002). Going malignant: The hypoxia-cancer connection in the prostate.
The wild-type, mutant USP2a as well as wild-type and mutant Unp (DeSalle Bioessays 24, 749–757.
et al., 2001) genes were inserted in pcDNA3.1 expression vectors and tran-
Kuhajda, F.P. (2000). Fatty-acid synthase and human cancer: New perspec-siently transfected into LNCaP cells with Lipofectamin Plus reagent (In-
tives on its role in tumor biology. Nutrition 16, 202–208.vitrogen, Carlsbad, CA). Forty-eight hours after transfection, Cycloheximide
(25 g/ml) was added to the medium. At indicated times, the cells were
Kuhajda, F.P., Pizer, E.S., Li, J.N., Mani, N.S., Frehywot, G.L., and Townsend,
washed, harvested into 2 ml ice-cold phosphate-buffered saline, pelleted
C.A. (2000). Synthesis and antitumor activity of an inhibitor of fatty acid
by centrifugation, and protein extracts immunoblotted with the indicated
synthase. Proc. Natl. Acad. Sci. USA 97, 3450–3454.
antibodies.
Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A.Y., Qin, J., and Gu, W.
Immunohistochemistry and immunofluorescence (2002). Deubiquitination of p53 by HAUSP is an important pathway for p53
Immunohistochemistry was performed with the USP2a rabbit polyclonal stabilization. Nature 416, 648–653.
antibody we generated, on 5 m tissue microarray sections of formalin-
Lin, H., Keriel, A., Morales, C.R., Bedard, N., Zhao, Q., Hingamp, P., Lefran-fixed, paraffin-embedded prostate adenocarcinoma and its adjacent normal
cois, S., Combaret, L., and Wing, S.S. (2000). Divergent N-terminal se-tissue from a database we previously characterized (Singh et al., 2002b).
quences target an inducible testis deubiquitinating enzyme to distinct subcel-The study was carried out in an automated immunostainer, the Optimax
lular structures. Mol. Cell. Biol. 20, 6568–6578.Plus (BioGenex, San Ramon, CA). Antigen-antibody reactions were revealed
with standardized development times, using the streptavidin method with Lin, H., Yin, L., Reid, J., Wilkinson, K.D., and Wing, S.S. (2001). Divergent
diaminobenzidine (DAB) as substrate. Five representative cores per patient N-terminal sequences of a deubiquitinating enzyme modulate substrate
were scored for expression of cytoplasmic USP2a as previously described specificity. J. Biol. Chem. 276, 20357–20363.
(Rossi et al., 2003). Immunofluorescence was performed as described (Wal-
Naviglio, S., Mattecucci, C., Matoskova, B., Nagase, T., Nomura, N., Ditregny et al., 2001).
Fiore, P.P., and Draetta, G.F. (1998). UBPY: A growth-regulated human
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